Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SOMERVILLE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced a planned...
-
SOMERVILLE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced a planned...
-
Presented new data in non-human primates (NHP) for sickle cell disease (SCD), where RNA Gene Writer achieved approximately 40% and 60% of long-term hematopoietic stem cells (LT-HSCs) with at least one...
-
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150...
-
SOMERVILLE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced three...
-
Award will support development of a single dose in vivo chimeric antigen receptor T cell (CAR-T) therapy to retrain immune cells directly within the body to fight cancer and autoimmune diseases using...
-
Presented new preclinical data in non-human primates (NHP) for alpha-1 antitrypsin deficiency (AATD) and phenylketonuria (PKU), where RNA Gene Writer achieved an estimated 76% and 70% editing in...
-
SOMERVILLE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced seven...
-
SOMERVILLE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and...
-
In vivo proof-of-concept achieved in humanized mice and non-human primates (NHPs) using Gene Writers encapsulated in proprietary lipid nanoparticles (LNPs) targeting long-term hematopoietic stem cells...